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ABSTRACT

The oxidized and reduced forms of ascorbic acid (AA) are reactive and
unstable compounds making their measurement difficult. Detection of small
amounts of AA and dehydroascorbic acid (DHAA) is essential for determining
the biochemical function of the vitamin in cells and subcellular organelles.
While a variety of techniques exist which detect millimolar levels of AA, accurate
assessment of pmol levels of AA and DHAA in a variety of tissues has not been
perfected. In the present study, a method was developed for quantitation of AA
and DHAA that combines HPLC separation with the advantages of increased
sensitivity and selectivity available with coulometric electrochemical detection.
Tissues were homogenized in 0.3% meta-phosphoric acid containing 1 mM
thiourea and 0.1 mM EDTA. Portions of the homogenates were either placed in
10% meta-phosphoric for AA analysis or in a 120 mM sodium phosphate buffer
(pH 7.2) containing 0.1 mM EDTA and 1 mM thiourea, for total AA (AA +DHAA)
measurement. Total AA was determined by reducing the endogenous DHAA in
a sample with 10 mM p-mercaptoethanol and allowing the reduction to occur for
10 minutes at room temperature. The reaction was stopped with the addition of
10% meta-phosphoric acid.
The developed method was extended to assess the levels of AA and DHAA
in nondiabetic and diabetic rat liver, kidney, brain and adrenal tissues. Results
indicated that the AA levels in diabetic liver and kidney tissues were
significantly less than control levels but there was no difference in AA levels in
diabetic and nondiabetic brain and adrenal tissues. When compared to
controls, DHAA concentration was greater in diabetic rat liver, kidney, and
adrenal giands but not in brain tissue.

INTRODUCTION

I. History of Ascorbic Acid
Scurvy was first reported in the year 1498 and although awareness of scurvy
existed for centuries, its cause was unknown. Symptoms of scurvy included
swelling and bleeding of the gums, swelling of the legs, muscular ache, bone
pain, weakness, hyperkeratosis, and hemorrhage of small blood vessels.
Scurvy was thought to result from infection, toxication, or faulty diet. Studies
eliminated the first two possible causes and it was concluded that scurvy was a
nutritional disease (1).
Results of early studies showed that fat soluble A factor and water soluble B
factor were essential nutrients. In 1919, Drummond designated a third essential
nutrient as water soluble C factor (2); this was thought io be the antiscorbutic
factor sought after for many years. However, it wasn't until 1928 that a
Hungarian scientist, Albert Szent-Gyorgyi, working at Cambridge, first achieved
the isolation of vitamin C (3). He observed that there was a high concentration
of a powerful reducing chemical in the adrenal cortex. From his analysis of the
crystals isolated from the adrenal cortex, he determined the molecular weight of
the reducing agent and that the only elements contained in the compound were
carbon, oxygen, and hydrogen. The ratio of these elements was shown to be
6 :6 :8, respectively, and so he gave it the name hexuronic acid. He also isolated
this powerful reducing agent from cabbage and orange juice, two substances
known to protect sailors from scurvy. However, there was disagreement as to
whether hexuronic acid was really the antiscorbutic factor. Most of the
1

2

controversy arose because of experiments in which the addition of these
crystals to experimental guinea pig diets failed to prevent scurvy (4). The
suggestion was (5) that in their method of preparing the crystals for the animals
diet, an oxidation step was involved where most of the ascorbic acid (AA) was
likely lost. In 1932, two separate studies (6, 7) reported that crystals obtained
from lemon juice, when fed to guinea pigs at 0.5 mg per day, protected them
from scurvy. This confirmed the initial hypothesis that hexuronic acid was the
antiscorbutic factor. Hexuronic acid was first synthesized in 1933 by Haworth
and Hirst (8) and renamed AA. Since that time, understanding the vital
functions of vitamin C and its availability in food sources has been a major
nutritional research focus.
II. Metabolism of Vitamin C
The ability to synthesize AA from carbohydrate sources, namely D-glucose
or D-galactose, through the glucuronic pathway, is retained in a wide variety of
plant and animal species. The synthetic ability is absent in humans, other
primates, guinea pigs, insects, invertebrates, fish, and certain bats and birds (9)
In terms of evolution, the synthesis of AA apparently began in the kidney of
amphibians and reptiles and was transferred to the liver of mammals but lost in
guinea pigs, flying mammals, and primates. The inability to synthesize AA
results from the loss of the genetic material coding for the terminal enzyme, Lgulono oxidase (9, 10, 11). Ascorbic acid is required in the diet of species
deficient in this enzyme.
The intestinal absorption of AA is an active process in scurvy prone animals
but is a passive process in other animals (12). It was determined that the
process in scurvy prone animals is that of Na+-dependent coupled-carrier
transport (12, 13) across the brush border. The active AA absorbance
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mechanism becomes saturated when the concentration of the vitamin is
increased. This concurs with evidence that the intestinal absorption of AA
decreases with increasing intake of the vitamin (14).

Fresh solutions of

dehydroascorbic acid (DHAA) were also shown to retain nutritional or
antiscorbutic activity (4, 15).

It was determined that this antiscorbutic activity is

associated with DHAA's intestinal absorbance that occurs through a process of
facilitated diffusion across the brush border, and subsequent reduction to AA
(16,17).
Transport of AA between plasma and tissues was also found to be by an
active process in most tissues. Dehydroascorbic acid was shown to be the
preferred form taken up by human neutrophils (18) and erythrocytes (19), and is
quickly reduced to AA after it is taken up by the cells. Dehydroascorbic acid is
continuously formed when AA is oxidized in the body. Its concentration is
maintained at very low levels in tissues by mechanisms that recycle it to AA.
Compiled tables of AA content in human organs indicate that the pituitary' and
adrenal glands and the leucocytes contain the highest concentration of AA (20).
The ocular tissues, brain, liver, and spleen also have relatively high
concentrations when compared to plasma levels. Plasma levels are
approximately 0.4-1.0 mg/100 g wet tissue (100 times less than the
concentration in the pituitary gland). The low levels of AA found in the plasma
indicate that transfer of the vitamin from plasma to tissue occurs against a
concentration gradient and therefore must be an active process.
Metabolism of AA and DHAA is governed by a variety of specific and
nonspecific mechanisms. For example, AA is oxidized to a free radical
intermediate, semidehydroascorbate or ascorbate free radical (AFR), which is
detected by electron spin resonance (21, 22). Ascorbate free radical is
relatively nonreactive when compared to other free radical species. It can either
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react with another AFR to regenerate AA or it can reaci with other radicals to
terminate their propagation (Fig. 1). An enzyme, AFR reductase, has been
described in rat liver (23), bovine adrenals, and a variety of rat and guinea pig
tissues (24, 25). This enzyme reduces the AFR back to AA. In plants, ascorbate
oxidase (EC 1.10.3.3), a copper containing enzyme, catalyzes the reaction of
AA and O2 to give DHAA and water (26). In tissues (17, 27, 28, 29) and plants
(30), dehydroascorbate reductase (EC 1.8.5.1) converts DHAA to AA, using
glutathione as a reducing agent. Some believe that, in mammals, DHAA is
converted to AA mainly by nonenzymatic means (31, 32). Dehydroascorbic
acid is hydrolyzed irreversibly to 2,3-diketogulonic acid (DKG) (Fig. 2), which is
then rapidly degraded to other products such as xylose, threonic acid, xylonic
acid, and lyxonic acid.

III. Biochemical Roles of Ascorbic Acid
Ascorbic acid has many diverse roles in the body. Most of these are
attributed to its reducing and chelating abilities (33). One of its well known
functions involves the formation of the mature collagen molecule. Ascorbic acid
serves as a reducing agent for the hydroxylation of proline contained in the
procollagen molecule (34,35). It is necessary for activation of prolyl
hydroxylase (36), an Fe++ requiring enzyme that carries out hydroxylation of
proline. Ascorbic acid presumably keeps Fe++ in its reduced or active state.
Ascorbic acid is also essential for hydroxylation reactions in the biosynthetic
pathway of muscle carnitine (34, 35, 37). Two of the five steps in the pathway
involve reactions where AA is required for the enzymes to perform
hydroxylation. Studies show that vitamin C deficient guinea pigs have low
carnitine concentrations (38).
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Ascorbic acid also plays a vital role as an antioxidant.

Ascorbic acid is

suggested to play a role in the protection of various tissues against free-radical
damage induced by various agents including cigarette smoke, radical species
generated from white blood cells, and photooxidative damage (39). It
accomplishes this task either directly by reacting with free radicals generated in
the aqueous phase of the cell, or indirectly by revitalizing the antioxidant
properties of vitamin E (alpha-tocopherol) (39). Ascorbic acid directly
scavenges superoxide radical (40, 41), hydroxy free radical (42) and singlet
oxygen (43) and is an effective inhibitor of lipid peroxidation (39). Lipid
peroxidation occurs in areas rich in polyunsaturated fatty acids (44). Cell
membranes contain large amounts of unsaturated fatty acids and are subject to
damage which could result in cellular death (45) from unchecked peroxidation
of the membrane lipids. Vitamin E is a fat soluble antioxidant found in the cell
membranes. !t interrupts the chain reaction that occurs after initial free radical
attack on a membrane lipid by reacting with the generated lipoxy radical,
resulting in vitamin E becoming a reactive free radical, the a-tocophero! radical.
AA regenerates the a-tocopherol radical by reducing it back to a-tocopherol
(46, 47). In this way, vitamin C protects the antioxidant capacity of vitamin E.
Vitamin C is also required in the nervous system for synthesis of
norepinephrine. Dopamine-p-hydroxylase is the enzyme that catalyzes the final
step in the formation of norepinephrine directly from dopamine (48). The
enzyme requires Cu++ as a cofactor and Cu++ acts as an intermediate
accepting electrons from AA; then Cu++ transfers the electrons to oxygen to form
H2O. Ascorbic acid is also involved in the processing of many neuropeptides.
Ascorbate dependent monooxygenase, called peptidylglycine a-amidating
monooxygenase (PAM), discovered in the pituitary (49, 50), catalyzes the
conversion of peptides ending in glycine to their corresponding oc-amidated
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peptide by a mechanism similar to dopamine-p-hydroxylase (51, 52). PAM
requires Cu++, AA, and O2 for optimal activity. The process of a-amidation of
peptides is an important mechanism in the biosynthesis of neuroendocrine
peptides including a-melanocyte stimulating hormone (a-MSH), thyrotropin
releasing hormone, oxytocin, vasopressin, and cholecystokinin (53, 54, 55).
Other roles of vitamin C include detoxification and metabolism of numerous
compounds, occurring through the cytochrome (P450) mixed function oxidase
(MFO) system. MFO is found predominantly in liver microsomes and reticulo
endothelial tissues and is a system which includes enzymes that hydroxylate
and methylate toxic agents produced by the body, such as bilirubin and steroid
hormones (56). Numerous studies (57, 58) have shown that there is a
relationship between the MFO system and AA in which increased drug
metabolism decreases levels of AA and also decreased levels of AA hinders the
drug metabolizing ability of MFO; however, there is no direct evidence for the
site of action of AA. Ascorbic acid is also involved in cholesterol metabolism
occurring within the MFO system although its site of action is again unknown.
Studies suggest that a vitamin C deficiency in guinea pigs leads to a reduction
in cholesterol metabolism (59).
Other functions of AA include facilitation of iron absorption (60), association
with synthesis of prostaglandins, and involvement in the functioning of the
immune system (61). Ascorbic add may play an important role in a redox
system involving NADH-free radical reductase, which functions in membrane
energetics and in the regulation of cell growth, and is found in cell membranes
and organelle membranes (62).
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IV. Ascorbic Acid Metabolism in Diabetes
Ascorbic acid metabolism is abnormal in diabetic humans and animals, but
disagreement exists as to how it is altered. For example, several studies have
shown that plasma levels of AA in diabetic patients are significantly decreased
while DHAA levels are increased (63, 64, 65). Other studies found normal
DHAA levels in the plasma of diabetic patients (66, 67). Despite their ability to
synthesize AA, decreased levels of AA are reported in various tissues of rats
that were made diabetic with alloxan (68). Few studies have determined tissue
levels of DHAA in diabetic animals but at least one attempt was made to
measure levels of both AA and DHAA in the plasma, liver, testes, and kidneys of
diabetic and non-diabetic rats (69). In this case an increase in DHAA levels was
found only in the plasma; however, levels of AA were significantly decreased in
all tissues except testes.
The mechanism by which the decrease in AA in diabetic animals occurs is
not well understood. Mann (70) noted the structural similarity between L-AA
and D-glucose and suggested that both may be involved in the same membrane
transport system. He formulated two hypotheses to explain the decrease of AA
that occurs in hyperglycemia (71). First, he proposed that the transport of AA
across the cell membrane is hindered by glucose. Assuming they share a
common transport mechanism, hyperglycemia would saturate the carrier with
glucose. His second hypothesis was that the transport of AA in certain tissues is
accelerated by insulin. In the absence of insulin a decrease in transport of
vitamin C would occur. Later, Mann (72) showed that D-glucose inhibited the
transport of DHAA into human red-blood cells, which are non-insulin dependent
tissues. Other researchers observe inhibition of AA transport with glucose in
human lymphocytes (73) and human cardiac endothelial cells (74) and
concluded that glucose and AA share a common transporter (75).
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It is also suggested that there may be a decreased number of glucose
transporters in the plasma membrane of diabetic leukocytes, and since AA and
glucose share the same transporter, this can explain the decrease in AA
observed in diabetic tissues. This conclusion was deduced from studies (68) in
which the rate of DHAA uptake by blood granulocytes and mononuclear cells
was slower and the plasma concentrations of AA lower, among persons with
diabetes mellitus. Vmax transport rates for DHAA, 2-deoxyglucose and 3-omethylglucose were decreased each to the same degree in diabetic cells but
Km values were not different from those observed in non-diabetic cells.
Dehyroascorbic acid is structurally similar to alloxan, a compound used
experimentally to induce diabetes. It is known to be toxic and daily intravenous
injections of DHAA into rats at a dose of 20 mg/kg was found to result in lasting
hyperglycemia after 3 weeks (76, 77). A third study confirmed this effect and
attributed it to damage sustained by the beta cells of the pancreas (78).
The disturbance of AA metabolism in diabetes is of interest because it may
be an important factor in the pathogenesis of many diabetic complications (74,
79, 80, 81), such as cataract, keratopathy, retinopathy, neuropathy,
microangiopathy, and nephropathy. In one study (82), it was found that
diabetic subjects had low plasma ascorbate levels but those with retinopathy
had significantly lower plasma ascorbate status compared to diabetic subjects
who did not have vascular complications.
Mann and Newton (72) proposed that a decrease in AA levels in tissues of
diabetic patients would lead to the development of a "local scurvy" due to
impaired transport. The resulting lesion would not be the same as classical
scurvy since the deficit is in a local AA supply rather than an extracellular
supply. Ascorbic acid is also important in regulating the intracellular redox state
and scavenging reactive free radicals. Therefore, AA deficiency may lead to

9
increased susceptibility to oxidative damage in diabetic subjects. Ascorbic acid
deficiencies may also be responsible for some of the collagen abnormalities in
diabetes, such as decreased capillary integrity and poor wound healing. In
addition, both DHAA and 2,3-diketogulonic acid, oxidation products of AA, are
known to initiate cross-linking of lens proteins (83, 84, 85).
The sorbitol or polyol pathway is implicated as a source of disturbances that
lead to various complications of diabetes (86, 87), including cataracts,
neuropathy, retinopathy, and nephropathy. The sorbitol pathway involves the
reduction of D-glucose to sorbitol catalyzed by aldose reductase and the
oxidation of sorbitol to fructose by sorbitol dehydrogenase. Normally the flux of
glucose through the sorbitol pathway is very low but it can be increased and
has been reported to account for 1/3 of the glucose metabolism in rabbit lens at
high glucose concentrations (86). A consequence of hyperglycemia in diabetes
is increased metabolism of glucose by the polyol pathway. Sorbitol is not
permeable to cell membranes and tends to accumulate in the cell.

There is no

known physiological role for sorbitol. Levels are negligible in most tissues but
under hyperglycemic conditions, the accumulation of sorbitol in tissues is
increased. Accumulation of sorbitol is found in diabetic tissues in proportion to
the concentration of extracellular glucose in sensitive tissues (87). Aldose
reductase inhibitors prevent the buildup of sorbitol, which is thought to decrease
the propensity for diabetic complications. The interaction between AA and the
sorbitol pathway is not well understood, but AA supplemented patients are
found to have reduced erythrocyte sorbitol accumulation by 27-56% depending
upon the dosage of AA given (79). Other studies have shown that low plasma
AA levels in diabetic rats could be normalized by dietary AA supplement and
also by the aldose reductase inhibitor, tolrestat.(80).
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v. Measurement of AA and DHAA
Since AA was first discovered to be the antiscorbutic factor vital to our diets,
researchers were interested in determining the basic biochemistry of the
vitamin, its content in foods, and tissue concentrations associated with disease.
Attainment of this knowledge required the development of assays to measure
levels of the vitamin in various substances. Earlier developed assays were
non-specific and not satisfactory for detailed work. Most assays involving
measurement of AA and DHAA take advantage their potential to function in a
redox system.
Methods developed include fluorometric, spectrophotometric,
chromatographic, and colorimetric assays. One of the earliest (88) and most
frequently used methods involves the ability of AA to reduce and subsequently
decolorize the indicator, 2,6-dichlorophenol indophenol. A limitation of this
method is its nonspecificity in that other reducing agents are able to decolorize
the indicator. Another colorimetric assay developed involves the ability of
DHAA to react with 2,4-dinitrophenylhydrazine to form an osazone and then
conversion of osazone to furfural which can be colorimetrically detected (89).
However, this method is also nonspecific because others compounds in the
samples are capable of reacting to form osazones.
Spectrophotometric methods are also used and involve direct detection
where ultraviolet light absorption of AA (265 nm) and of DHAA (230-280 nm) is
followed. These assays have a limited value because of interference by many
other biological substances absorbing in this region.
Chromatographic methods hold the most promise for specific methods in the
detection of AA, DHAA, and 2,3-DKG. A method involving paper
chromatography was developed to measure AA and various breakdown
products (90). However, high-pressure liquid chromatography (HPLC) has
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proven to be a powerful and efficient technique for the separation, identification,
and quantitation of small quantities of AA and its metabolites. Combining HPLC
with other methods allows an assay, that was nonspecific before the addition of
HPLC, to become specific because the separation of the compound of interest
from other constituents of the sample can be achieved. Numerous procedures
using HPLC were developed to measure AA in foods and tissues (91, 92, 93).
Variations in the procedures include the column type, mobile phase, detection
system, and stabilization of samples.
Ascorbic acid is subject to oxidation in biological solutions and is therefore
unstable. The first oxidation product, DHAA, Is extremely unstable and reactive.
It is rapidly hydrolyzed irreversibly to DKG with a half life of six minutes at a
temperature of 37° C and pH 7.0 (94). Metaphosphoric acid (MPA) and
trichloroacetic acid (TCA) are the reagents of choice for stabilizing AA and
DHAA acting by precipitating proteins and maintaining a reduced pH in the
sample (95).

Long term stability of AA in acidic medium has been reported

from 30 days at -20°C (96) to 5 weeks at -70°C (97).
Detection methods used with HPLC include ultraviolet (98, 99, 100),
radiochemical (101), fluorometric (102), and electrochemical analysis (103,
104, 105). These methods all require stabilization of the sample and vary in
sensitivity. One method to analyze AA and DHAA involves derivatization with
o-phenylenediamine to separate DHAA from AA (106).

The AA contained in

the sample is measured electrochemically and the DHAA is measured by UV
analysis. The use of HPLC and electrochemical (EC) detection in the analysis
of AA has been applied to food and animal tissues with excellent success,
whereas the application of HPLC-EC to the measurement of DHAA in a variety
of tissues has not been as successful, mainly due to the instability of the
molecule. However, electrochemical detection of AA and DHAA in the samples
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offers many advantages. It requires small injection volumes, has increased
selectivity for AA, and is capable of low detection limits.
There are two types of EC detection, amperometric and coulometric.
Theoretically, all EC detectors are amperometric, meaning the potential applied
to the detecting electrode is held constant while the resulting currents are
monitored as analytes flow past the detector. Most amperometric sensors
cause approximately 1-5% of the passing analyte to undergo charge transfer.
However, coulometric electrochemical detection utilizes porous, flow-through
electrodes. An oxidation reaction takes place at the surface of the electrodes
and the charge that is transferred is measured. In this way, the electrode reacts
with 100% of the analyte, resulting in increased sensitivity.
Detection of AA by electrochemical detection offers the advantage of
increased selectivity for AA. This is accomplished by placement of the
electrodes in series, where the first electrode reacts with and eliminates
contaminating compounds so they will not interfere at the second electrode,
where oxidation of AA occurs and is detected. Dehydroascorbic acid is not
electrochemically active and so it must be measured indirectly. The procedure
involves the measurement of total AA (DHAA + AA). Ascorbic acid is measured
first, DHAA is then reduced to AA in the sample, and then subsequent
measurement of total AA can occur. The challenge in measuring DHAA in
biological samples is its extreme instability. Success in measuring DHAA with
electrochemical detection has almost exclusively occurred in biological fluids
including plasma (97, 98, 107, 108, 109), protein free human milk (107),
cerebrospinal fluid (109), and leukocyte extracts (107) rather than in whole
tissues.

STATEMENT OF THE PROBLEM

The purpose of the present study was two-fold. The first purpose was to
develop a sensitive and reliable method for accurately measuring ascorbic acid
(AA) and dehydroascorbic acid (DHAA) in mammalian tissues. The challenge
in accomplishing this goal is the instability of DHAA. The verification of a
reliable assay requires the assay's ability to linearly recover exogenous DHAA
and AA added to tissue homogenates. The second objective was to apply the
method to the measurement of AA and DHAA in normal and diabetic tissues.

MATERIALS AND METHODS

I. Experimental Animals
Male Spraque-Dawley rats, obtained from Bio-Labs Corporation (St. Paul,
MN), were used for this study. The number of animals used in the determination
of AA and DHAA in normal and diabetic tissues was 23; the number used in the
initial development of the method was undetermined since tissues were
donated by another research group using the same strain of rats.
The animals were kept at the Animal Resource Facility (UND Medical
School, Grand Forks, ND). Environment conditions were maintained at a
temperature of 72°F and a 12 hour/12 hour light/dark cycle. Animals were kept
in stainless steel, mesh floor cages with an area of 160.9 in2. Two animals
were housed in each cage. The only time the animals were removed from this
environment was for tissue analysis. Rats were maintained ad libitum on Purina
Rodent Lab Chow 5001 and water.

II. instrumentation for Analysis
A) High-Pressure Liquid Chromatography (HPLC) System
The equipment used for analysis consisted of a Beckman System Gold
HPLC containing two Beckman Model 11 OB high pressure pumps, a System
Gold 502 autosampler with a 20 pi injection loop, and a Waters Radial
Compression Separation System consisting of a radial compression module
model RCM-100 with a Waters Radial-Pak cartridge, Resolve C i8 reversephase column. Data was collected with the assistance of a System Gold
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Analog Interface Module 406 and an IBM model 55 SX personal computer. The
computer was used to integrate and interpret the resulting chromatogram, with
the aid of System Gold software. Results were printed on an Epson FX-850
printer and data were stored on floppy diskettes. The samples were injected
onto the column and AA was eluted with a mobile phase consisting of 0.2 M
KH2P0 4 ( pH 3.0, filtered through 0.22 pm filters (Miilipore Corp., Bedford, MA)
prior to its use. The flow rate was maintained at 1 ml min'1. The system was
cleaned periodically with 10% methanol and then equilibrated with the mobile
phase prior to use.

B) £ifigtEQchjemicaiJpgtggtQ.r. System
1) Instrumentation
The content of AA in the samples was quantified by means of an ESA Model
5100A Coulochem Multi-Electrode Electrochemical Detector (ESA, Inc.,
Bedford, MA) containing an ESA Mode! 5010 Analytical Cell. In-line high
pressure carbon filters (ESA, Inc.) were placed between the analytical column
and the electrodes.
2) Initialization,.of .Electrochemical Detector for AA Analysis
The appropriate detector settings for optimal AA sensitivity and selectivity
were determined by making a current-voltage (C-V) curve, which is a graph of
response (current) versus potential (voltage). By reviewing the C-V curve, the
optimal voltage was selected for both electrodes so a maximum response was
obtained while minimizing background noise from interfering compounds.
The procedure for making a C-V curve begins with the preparation of
samples containing the analyte of interest, AA. Since DHAA is not
electrochemically active, the developed method involved detection of
endogenous AA and total AA. Total AA included endogenous AA and
endogenous DHAA that was reduced to AA. A 1 mM solution of AA was

prepared in double glass distilled water and kept on ice until analysis. The
model 5010 Analytical Cell contains two coulometrically efficient porous
graphite working electrodes placed in series. In preparing the C-V curve,
detector 1 is set at a very low potential (-0.5 V) because the optimal potential for
detector 2 needed to be determined. The potential at the detector 2 w'as varied
with each injection. To begin the determinations, detector 2 was set at -0.4 V,
the AA solution was injected and the response was recorded. For the next
injection, the potential at detector 2 was increased by 0.05 V to -0.35 V, the
sample injected, and the response recorded. This procedure was repeated
until the response had reached its maximum, i.e., there was no change in
response (peak height) for increases in potential.

III. Experimental Compounds
A) Mobile Phase
The mobile phase consisted of 0.20 M KH2PO4 that was brought to a pH of
3.0 with KOH. The final solution was filtered through a 0.22 jim filter (Millipore)
before its use. Monobasic potassium phosphate and 85% ortho-phosphoric
acid were purchased from Fischer Scientific and were HPLC grade. Potassium
hydroxide (45%) was prepared from a stock of KOH pellets purchased from
Fisher Scientific and was A.C.S. grade.
B) Buff8L
The buffer used in the analysis of DHAA consisted of 120 mM dibasic
sodium phosphate brought to a pH of 7.2 with 120 mM monobasic sodium
phosphate. The buffer also contained 0.1 mM EDTA and 1mM thiourea for
stabilization of AA and DHAA. Dibasic sodium phosphate was purchased from
Fischer Scientific and its quality was enzyme grade. Monobasic sodium
phosphate was purchased from Matheson, Coleman and Bell and was A.C.S.

grade. The EDTA was purchased from Sigma and was Sigma grade. The
buffer was also filtered through a 0.22 jim filter (Millipore Corp. ) before use.
C) Mela-Phosphoric Acid
Two solutions of meta-phosphoric acid were used in the assay. For initial
stabilization and homogenization of the tissue sample, a 0.3% solution was
used containing 1 mM thiourea (Sigma), and 0.1 mM EDTA (Sigma). The
second solution was a 10% meta-phosphoric solution also containing 0.1 mM
EDTA and 1 mM thiourea and was used for the reaction involved in the analysis
of AA and the termination of the reducing reaction for measurement of total AA.
The solutions were made by dissolving meta-phosphoric acid in double glass
distilled water. The meta-phosphoric acid was purchased from Fisher Scientific
and was A.C.S grade.
D) B-Mercaptoethanol
The reducing agent, p-mercaptoethanol, or 2-mercaptoethanol, used in the
analysis was purchased from Sigma Chemical Co. (St. Louis, Mo.).

IV. Procedure for Analysis
A) Obtaining the Tissue samples
Tissues were obtained from rats four weeks after injection with
streptozotocin or vehicle. After anesthetization of the rats with ether, various
tissues were surgically removed. Blood was either removed through a heart
puncture or the common iliac artery, which was the technique of euthanizing the
animals. The tissues were weighed and immediately placed in 3 mis of 0.3%
meta-phosphoric acid, 0.1 mM EDTA, and 1 mM thiourea per gram of tissue to
stabilize the analytes of interest.

B) Analysis of Compounds
1) Ascorbic Acid
Samples were placed in meta-phosphoric acid and homogenized using
tissue grinders purchased from Curtin Matheson Scientific, Inc. (Eden Prairie,
MN). The homogenates were centrifuged at 19,000g for 20 minutes. One
hundred pi of the supernatant were removed and used for AA analysis. Nine
hundred pi of 10% meta-phosphoric acid were added to the sample to stabilize
and allow for analysis by HPLC.
2) Dehvdroascorbic Acid
Total AA analysis included endogenous AA and endogenous DHAA that
was reduced to AA. By subtracting the endogenous AA, determined in the
previously mentioned assay, from the total AA, the endogenous DHAA could be
quantified. One hundred pi of the supernatant were removed from the
homogenized sample that was centrifuged as for the AA determination. The
reducing agent, [3-mercaptoethanol, was added to the sample to a final
concentration of 10 mM in 390 pi of sodium phosphate buffer (pH 7.2). This
solution was allowed to react for 10 minutes at room temperature and the
reaction was stopped with the addition of an equal volume of 10% metaphosphoric acid.
3) Sample Analysis using HPLC-EC System
The samples that were analyzed were either analyzed immediately or frozen
for later analysis. The data generated from an individual sample were obtained
in the form of a chromatogram in which the AA peak was identified and peak
area integrated. Unknowns were compared to standard peaks of known AA
concentration, to yield a concentration of AA in the sample.
The standards were made at the time of analysis. They were prepared by
making solutions of different concentrations of AA in 5% meta-phosphoric acid

and injecting them into the HPLC-EC system. A computer progam called
System Gold version 510 was used to integrate peak areas.

v. Determination..of ApprQpilate-A&sgy Conditions.
A) Stability..Qf-the.ErosenJSamplfi
Liver homogenates were used to determine the stability of prepared
samples ready for analysis but frozen for various lengths of time before
analysis. The samples were acidic since all contained meta-phosphoric acid.
B) Assay Conditions
The determination of appropriate assay conditions for the reduction of DHAA
was accomplished by varying one of the conditions while holding the others
constant. The optimal condition was chosen on the basis of percent conversion
of DHAA to AA of an exogenously added amount of DHAA in the samples. Liver
samples were used for the determinations of optimal conditions. The
exogenous DHAA that was added was from a solution of AA which was
oxidized to DHAA by bromination. The bromine was removed by blowing a
stream of N2 over the solution. The conditions that were varied were reaction
temperature, reducing agent concentration, reaction time and buffer pH.
C) Recoveries
In the determination of optimal reaction conditions, exogenous AA and
DHAA were recovered in a linear fashion from tissue homogenates. Recoveries
of exogenous DHAA and AA added to tissue samples and buffer were used for
verification that the assay was working. Ten pi of 10 mM AA was added to 100
pi of tissue homogenates, analyzed for AA in diabetic studies and addition of
890 pi of 10% MPA followed . Ten pi of 10 mM DHAA was added to 100 pi of
tissue homogenates, prepared from diabetic and nondiabetic animals followed
by addition of 380 pi of sodium phosphate buffer and 10 pi of (3-
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mercaptoethanol. The reaction was stopped with 500 pi of 10% MPA followed.
The exogenous AA and DHAA were also recovered from buffer in these studies
to evaluate the actual amount of AA and DHAA added to tissues.

VL Diabetic Studies
A) Streptozotocin Administration
Thirteen rats, 180 to 200 gram body weight, were made diabetic with a
single intraperitoneal injection of 75 mg streptozotocin (Sigma Chemical Co.)
per kg body weight. The streptozotocin solution was dissolved in 10 mM citrate
buffer with a pH of 4.5. Ten control rats received an intraperitoneal injection of
10 mM citrate buffer, pH 4.5.
B) Blood Glucose Measurements
in diabetic studies, blood glucose was measured to verify a diabetic state.
The GOD-Perid (Sigma) procedure, based on the oxidation of chromagen by a
coupled reaction involving glucose oxidase and peroxidase, was used to
establish blood glucose levels. Two-tenths of a ml of whole blood were placed
in 0.8 mis cold water. This ml of sample was added to 1.0 ml of 8%
Ba(OH)28H20. After 1 minute 1.0 ml of 2% ZnSO47H20 was added and the
mixture was vortexed. The precipitated protein was removed by centrifugation
at 1850 rpm for 15 minutes in a table top centrifuge at room temperature. Onehalf ml of the resulting supernate was removed as samples from control animals
and as samples from diabetic animals, 0.1 ml of supernate was diluted with 0.4
ml of water and analyzed for glucose concentration.
Two ml of the GOD-Perid reagent was added to the above test tubes and
the reaction was allowed to go to completion in 25 minutes at room temperature
and absorbance was determined at 505 nm. The assay contained a calibration
blank and 4 standards containing 0.005, 0.01, 0.03, and 0.05 mg glucose.
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Using the values obtained from the standards and the appropriate dilution
factors, the concentration of glucose was calculated.

VH. Statistical Analysis
Data analysis included analysis of variance and linear regression.
The accepted level of significance for F0bs was a<0.05. Linear regression was
used to produce standard curves for the recovery of exogenous AA and DHAA
from buffer and tissues. Multivariate ANOVAS were performed to compare the
conditions tested in the assays involving the determinations of optimal pH,
reaction time, reaction temperature, and reducing agent concentration.
Univariate ANOVAS were performed to compare the AA and DHAA
concentrations in diabetic and nondiabetic tissues.

RESULTS

I. C-V Curve
The results for the C-V (current to voltage) cl:, ve for AA are presented in
figure 3. Observations that can be made from this curve and the determination
of optimal potentials for both detectors are as follows. E0' is the formal potential
for AA. At potentials negative to E0' little or no oxidation of AA occurs. At
potentials positive to E0' the current quickly reaches its limiting value and the
half-wave potential, E1/2 is equivalent to the formal potential. The half wave
potential is defined as that potential at which current equals one-half of the
limiting value. Detector 1 is set at the foot of the C-V curve for the analyte of
interest. This is done to decrease background currents and prevent unwanted
peaks that result from eluants that oxidize at lower potentials than the analyte of
interest. The potential of detector 2 is set at the plateau of the C-V curve, where
maximum response is observed for the analyte of interest. The detector
potentials for optimal AA measurement were determined to be - 0.3 V for
detector 1 and 0.0 V for detector 2.

II. S ta b ility of Frozen Samples
Samples of liver homogenates were prepared for analysis of total AA (AA +
DHAA) and were frozen before HPLC-EC analysis. Samples were removed
from the freezer at various lengths of time after initial freezing and total AA was
measured. These values were then compared to initial total before freezing AA
concentration.
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The results are graphed in figure 4 and indicate that there is no significant loss
of total AA in the sample in a time period up to 55 days.
\

Hi. Conditions_f.Qf_Reducinq.PHAA to AA
The results for the determination of appropriate buffer pH, reaction time,
reaction temperature, and reducing agent concentration for the reduction of
DHAA to AA in tissue homogenates are presented in figures 5,6, 7, and 8. The
optimal conditions were selected by determining the maximum conversion of
exogenous DHAA to AA added to the reaction mixture. The process of making
DHAA through bromination of AA results in a loss of approximately 20% of the
original AA. In order to obtain actual values of AA, DHAA, and DKG in
commercial samples of AA and in DHAA solutions obtained from AA by
bromination, 14C radiolabelled AA was used. The radioactive AA is separated
by HPLC, where the degradation products of AA, DHAA and DKG, along with
AA are separated. The fractions are collected and the concentration of these
products is determined by counting the radiolabelled components by liquid
scintillation spectometry. The results presented in table 1 indicate that the
commercial radiolabelled AA is about 75% AA and 16% DHAA, therefore the
total AA (DHAA + AA) in the original sample is 91%. About 69% of the original
total AA results in DHAA after bromination with the remainder degrading to
DKG. Therefore, a 22% loss of DHAA is expected with bromination, so a 78%
or greater recovery of exogenous DHAA would be 100% of what is present.
Data are presented in this manner for the determination of optimal conditions.
In figure 5, the appropriate buffer pH was determined for recovery of DHAA
from a sodium phosphate buffer. Based on previous reports (110), three pH's
6.2, 7.2, and 8.2 were used for screening. It was determined that the recover/ of
DHAA at pH 8.2 was significantly less than the recovery at pH 6.2 and pH 7.2.
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Although greater recovery was not statistically significant at a pH of 7.2 it was
chosen as the buffer pH for the assay.
In figure 6, the results are presented for the determination of the optimal
reaction time for the reducing reaction. The conversion of DHAA to AA at times
2, 5, 10, and 20 minutes were all significantly different than conversion at time
zero and two minutes. The reaction time chosen for the assay was 10 minutes.
Figure 7 shows the results from experiments in which optimal reaction
temperature are shown. There was no significant difference in conversion of
exogenous DHAA to AA added to liver homogenates when the reaction was
carried out at room temperature or in ice. For convenience, room temperature
was chosen as the reaction temperature for the assay.
In figure 8, the results are presented for the determination of the optimal
concentration of reducing agent, (3-mercaptoethanol. A concentration of 1 mM
was not as effective as 5, 10, or 20 mM. The (3-mercaptoethanol concentration
for maximum conversion of DHAA to AA was chosen as 10 mM. From the data
presented in figures 5, 6, 7, and 8, the conditions for reducing DHAA to AA in
liver homogenates are: a buffer pH of 7.2, a reaction time of 10 minutes, a
reaction temperature at room temperature, and a 10 mM concentration of (3mercaptoethanol.

IV. Standard Curves of Recoveries
Figures 9, 10, and 11 are the results obtained from liver, brain, and kidney
homogenates, respectively, in which varying amounts of AA were added and
recovered. These figures indicate that AA was recovered in a linear fashion
from all homogenates.
Figures 12, 13, 14, and 15, are standard curves obtained from buffer, liver,
brain, and kidney homogenates, respectively, in which DHAA was added to the
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homogenates and recovered in a linear fashion using the reducing reaction
explained in the methods section.
The standard curves obtained for the recoveries of both AA and DHAA in
tissue homogenates indicates that stabilization and measurement of the
analytes is satisfactory and the method described is capable of accurately
measuring endogenous ievels of AA and DHAA.

v.
Once the optimal conditions for reducing DHAA to AA were established and
recoveries of AA and DHAA were verified, the method was applied to
measurement of endogenous levels of AA and DHAA in diabetic rats. Table 2
contains blood glucose measurements from diabetic and control rats used in
the study. Diabetic animals had significantly greater blood glucose
concentrations as compared to control animals. This measurement is used to
confirm that animals were in a uncontrolled diabetic state.
Figure 16 shows results of endogenous AA measurements in liver, kidney
and brain tissues from diabetic and control animals. Diabetic liver and kidney
tissues had significantly decreased levels of AA compared to control tissues.
There was no significant difference of AA levels in diabetic and control brain
tissues.
Figure 17 shows the results of endogenous DHAA measurements in liver,
kidney, and brain tissues from diabetic and control animals. Levels of DHAA in
diabetic liver and kidney were significantly increased compared to control liver
and kidney tissues. There was no DHAA detected in the nondiabetic livers.
There was no significant difference in the levels of DHAA measured in diabetic
and control brain tissues.
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In figure 18 (A & B) the results for the levels of AA and DHAA measured in
diabetic and control adrenal glands are shewn. There was no significant
difference in AA levels between diabetic and control adrenal glands. DHAA in
diabetic adrenal glands was significantly increased compared to levels found in
control adrenals, in which DHAA was not detectable.
Recoveries of exogenous AA and DHAA added to diabetic and control brain,
kidney, and liver tissues were done to verify that the assay was working.
Results are presented in figure 19 . Recoveries of AA and DHAA from both
diabetic and nondiabetic tissues were greater than 90%.

D IS C U S S IO N

Ascorbic acid has many important functions and is essential for the
maintenance of health. Since AA and DHAA levels in various tissues of healthy
subjects are maintained at very low levels, accurate detection of these
compounds is required. DHAA and AA are unstable and reactive compounds
making their measurement difficult, especially in tissues which contain
substances capable of reacting with AA and DHAA and therefore increasing
their instability. A highly sensitive, selective, and reliable method for measuring
DHAA in tissues has not so far been reported in the literature.
Methods for measuring AA and DHAA have improved with the advent of
HPLC combined with electrochemical (EC) detection. HPLC allows for
increased selectivity and EC detection utilizes the unique redox properties of
AA. Coulometric electrochemical detection increases the sensitivity of the
assay by completely oxidizing the analyte at the electrode's surface. The
detectors are set at potentials that are optimal for the oxidation of AA and thus,
for its determination. Assays for determining DHAA using HPLC-EC include
biological fluids, such as cerebrospinal fluid (109), plasma (97, 98, 107, 108,
109) human milk (107), and leukocyte extracts (107). These methods are
reliable for these fluid measurements but have not been extensively applied to
tissue samples. One method (98) involves derivatization of DHAA with 2,4diphenylhydrazine so that simultaneous measurement of AA by EC detection
and DHAA by ultraviolet detection is possible. However, low detection limits of
DHAA are not possible with this method, and therefore it is not satisfactory for
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determining differences in animal tissues that normally have very low levels of
DHAA. At least one group developed a method (108) which measures both AA
and DHAA in tissues, in addition to biological fluids, and foods. In this assay,
homocysteine is the reducing agent. The reaction converts endogenous DHAA
to AA, over a period of 30 minutes at room termperature and at a pH of 7.1, for
electrochemical measurement. The detection limits for this assay are
suggested to be 50 pg/20 pi injection volume, while the presently developed
method has detection limits of 2 pg/20 pi injection volume. The instability of
DHAA and AA is not appropriately addressed in their procedure. The reduction
of DHAA for 30 minutes at room temperature and pH 7.1 appears to be
inappropriate considering the half-life of DHAA is 6 minutes at a pH of 7.0 and a
temperature of 37°C (94).
Ascorbic acid is involved in a variety of functions in the body. It functions in
collagen formation (34, 35, 36), acquirement of energy for muscle tissues (34,
35, 37), synthesis of neurotransmitters and neurohormones (48-55), protection
against reactive and potentially damaging free radicals (39-47), and the
immune response (61). It is understandable then, that a deficiency of this
vitamin could produce some damaging effects. The symptoms of scurvy occur
when the deficiency is taken to its full extent, it is possible that there is an
intermediate level of deficiency that could produce clinical symptoms not exactly
similar to those seen in scurvy (72). The present study has shown that in
diabetic animals, there is a decrease in concentrations of AA and an increase in
DHAA in some tissues.
AA concentrations were decreased in diabetic liver and kidney but no
decrease was found in brain or adrenal tissues (Fig. 17 & 19). The mechanisms
for the decreased concentrations observed in diabetes are unclear. Mann (71)
proposed that there is competition for the transporter by glucose and DHAA .
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This then could be a possible explanation for decreased levels of AA since
hyperglycemia is associated with diabetes. The high glucose levels could more
effectively compete for available transport mechanisms. One problem with this
explanation is that a decreased concentration of AA was not observed in all the
tissues. Low concentrations of AA in diabetes could be associated with its high
metabolic turnover, resulting in increased consumption of AA by oxidation to
DHAA (64). This could explain low concentrations of AA found in diabetic
human tissues, in which intake of AA may not be adequate due to the rapid
turnover. In the present study, rats, which are capable of synthesizing ascorbic
acid, were evaluated. In this case, a decreased production of AA, one that is not
capable of meeting its rapid turnover, maybe a possible explanation for
decreased tissue levels of AA.
DHAA concentrations were increased in liver, adrenals, and kidney tissues
but not in brain tissues of diabetic rats (Fig. 18 &19). There are a few
possibilities to explain this occurrence. For example, an increased degradation
of AA from its rapid turnover in diabetic subjects could lead to increases in its
oxidized product, DHAA. There also could be an insufficiency in the
mechanisms that regenerate ascorbic acid from its oxidized products. For
example, reduction of glutathione levels in various tissues (111, 112) may
reduce the potential for nonenzymatic mechanisms to appropriately regenerate
ascorbate. Therefore, utilization of AA by its involvement in various biochemical
reactions could lead to a buildup of DHAA because at least one mechanisms for
regenerating AA is inadequate. Some tissues prefer DHAA as the form for
uptake. When DHAA is taken up by these tissues, it appears in the cell as AA
(113). Although the mechanism is unclear, it is possible that these tissues have
reducing mechanisms (i.e. proteins) in close proximity to the transporter that are
not optimally functioning. This would result in a decrease in tissue AA
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concentrations because of the tissue's inability to transport this form into the
tissue; and DHAA concentrations would be increased because of the tissue's
preference for uptake of DHAA and the subsequent decreased ability for DHAA
to be reduced.
It is known that in diabetes giycosylation of proteins occur that can reduce or
inhibit their activities (114,115). Altered AA metabolism in diabetics could result
from decreased function, due to giycosylation, of AA or DHAA transport proteins
or enzymes involved in keeping AA in its reduced form.
Altered AA metabolism in certain tissues could account for some of the
complications associated with diabetes. Decreased levels of AA may lead to an
accumulation of sorbitol since AA plays a role in inhibiting the sorbitol pathway.
AA inhibits this pathway either by competing for glucose entrance into this
pathway and thereby keeping the reaction products low, or by inhibiting the
enzymes responsible for this conversion of glucose to sorbitol. Sorbitol may be
a contributor in many of the diabetic complications (86, 87). Increased levels of
DHAA could also account for some of the diabetic complications. It is known to
be involved in giycosylation reactions and increased concentrations would
therefore be expected to increase these types of reactions (83, 84, 85). DHAA
does not retain the antioxidant capabilities that AA has which could be
associated with increased cell damage (116) . DHAA is also known to be toxic
to cell membranes (78). Studies have shown that diabetic patients with
complications, such as retinopathy, had lower plasma AA concentrations that
diabetic patients without complications (82).
It is interesting to speculate as to why brain tissue did not have altered levels
of AA and DHAA in diabetic compared to nondiabetic tissues. It may be that AA
is critical to the nervous system and is therefore, conserved. It is also possible
that whatever mechanisms account for the inappropriate metabolism of AA in
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other tissues are not involved in the brain. The fact that vitamin C is such an
important component in many biochemical reactions and that its metabolism in
diabetes is altered renders it an important part of the diabetic syndrome and
suggests further endeavors should be taken to understand its involvement in
this disease.

SUM MARY

A reliable method for measuring AA and DHAA was established. Its
reliability has been verified by recoveries of exogenous AA and DHAA in
mammalian tissues. Optimal conditions for reducing DHAA in tissue samples
were determined to be: a buffer pH of 7.2, a reaction time of 10 minutes, a
reaction temperature at room temperature, and a 10 mM concentration of (3mercaptoethanol.
AA and DHAA were measured in diabetic and nondiabetic rat tissues using
this method and the following results were obtained:
1. AA in the kidney of diabetic rats was 1/2 that of nondiabetic kidney.
DHAA in the diabetic kidney was 7 times more than nondiabetic
concentrations.
2. AA in diabetic liver was 1/2 that of nondiabetic liver. DHAA was 136
nmol/gram in diabetic liver and was not detectable in the nondiabetic
liver.
3. AA and DHAA concentrations in diabetic rat brain tissues were not
significantly different from the levels found in nondiabetic brain tissues.
4. AA concentrations in diabetic adrenal glands was not different from
nondiabetic concentrations. DHAA in the diabetic adrenai glands was
401 nmol/gram and was not detectable in the nondiabetic animal.
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Table 1
Composition of Radiolabeled AA and Prepared DHAA Solutions
Solution

%AA

n

AA Standard

j*

DHAA Standard

37

i

r~

v>

%DHAA

%DKG

74.9+1.2

16.2 ± 1 .0

8.9 ± 0.8

1.8 ±0.5

69.2 ± 2.7

29.1 ± 2 .9

DHAA was prepared by brominating a solution of AA and blowing off the excess bromine
with a stream of N2.
Values are expressed as means ± S. E.

Table 2
BLOOD GLUCOSE CONCENTRATION
n

[glucose]
mM

S.E.

Diabetic Rats

10

21.21 r

1 .085

Control Rats

10

6.504

0.311

*p =0.001
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FIGURE 2.

Metabolism of Ascorbic Acid
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FIGURE 3. C-V Curve for Ascorbic Acid Curve was made using a 1 mM
ascorbic acid solution. Detector one (D-i) was set at -0.4 V while the
potential at detector two (D2) was varied at increments of 0.05 V and the
response was followed.
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FIGURE 4. Stability of Frozen Samples of a Liver Homogenate
Samples were frozen after the reduction reaction (to measure total
AA) was completed by the addition of metaphosphoric acid.
Measurement of samples were taken at various intervals after being
frozen.
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FIGURE 5.

Determination of Optimal Buffer pH The pH for a 120 mM

sodium phosphate buffer used for the reducing reaction of DHAA to
AA in liver homogenates. Percent conversion of 1 mM DHAA to AA
added to liver homogenates in buffers of pH 6.2, 7.2, and 8.2 was
determined.
* p < 0.05 for pH 8.2 compared to pH 6.2 and pH 7.2
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FIGURE 6.

Determination of the Optimal Reaction Time The optima!

reaction time for the reducing reaction was evaluated by adding 1 mM
DHAA to liver homogenates and determining the conversion of DHAA
to AA when the reducing reaction was carried out at 0, 2, 5 10, and 20
minutes.
* p < 0.05 for time 0 minutes compared to 2, 5, 10, and 20 minutes
and for time 2 minutes compared to 5, 10, and 20 minutes
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FIGURE 7.

Determination of Optimal Reaction Temperature The

optimal reaction temperature for the reducing reaction involved in
measuring total AA was evaluated by adding DHAA to liver
homogenates. Conversion of the exogenous DHAA was determined
in homogenates in which the reducing reaction was carried out at
room temperature or on ice.
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FIGURE 8.

Determination of Optimal Reducing Agent

Concentration The optimal concentration of the reducing agent
concentration, (3-mercaptoethanol, was evaluated in liver
homogenates. One mM DHAA was added to liver homogenates
which then was reduced to measure total AA. Percent conversion of
DHAA in homogenates using 1,5, 10, and 20 mM p-mercaptoethanol
was determined.
* p < 0.05 for recoveries at 1 mM compared to 5, 10, and 20 mM
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FIGURE 9.

Standard Curve of Recovered Exogenous AA Added to

Liver Homogenates One mM AA was added to liver
homogenates in various amounts and recovered in a linear fashion
using the reducing reaction explained in the methods section.
R2 = 0.999
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FIGURE 10.

Standard Curve of Recovery of Exogenous AA Added

to Brain Homogenates One mM AA was added to brain
homogenates in various amounts and recovered in a linear fashion.
R2 = 1.000
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FIGURE 11.

Standard Curve of Recovery of AA in Kidney

Homogenates One mM AA was added in varying amounts to kidney
homogenates and recovered in a linear fashion.
R2 = 0.996
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FIGURE 12.

Standard Curve of Recoveries of DHAA Adds*? to

Buffer DHAA was added to buffer in various amounts and recovered
in a linear fashion.
R2 = 0.990
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FIGURE 13.

Standard Curve of Recoveries of DHAA in Liver

Homogenates DHAA was added to liver homogenates in various
amounts and recovered in a linear fashion by reduction to AA and
subsequent measurement.
R2 = 0.992
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FIGURE 14.

Standard Curve of Recovery of DHAA Added to Brain

Homogenates

DHAA was added to brain homogenates in varying

amounts and reduced to AA for measurement and recovered in a
linear fashion.
R2 = 0.996
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FIGURE 15.

Standard Curve of Recovery of DHAA From Kidney

Homogenates DHAA was added to kidney homogenates in
varying amounts, reduced to AA, and recovered in linear fashion.
R2 = 0.997
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FIGURE 16.

Endogenous AA in Diabetic and Control Rat Tissues

Endogenous AA levels in diabetic and nondiabetic rat brain, kidney,
and liver tissues were determined using HPLC-EC.
* p < 0.05 for diabetic compared to nondiabetic measurements
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FIGURE 17.

Endogenous Measurements of DHAA in Diabetic

and Nondiabetic Rat Tissues Endogenous DHAA levels in
diabetic and nondiabetic rat liver, brain, and kidney tissues were
determined by measurement of total AA and calculation of DHAA
based on these measurements and AA measurements.
* p< 0.05 for diabetic compared to nondiabetic measurements
ND = not detectable
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FIGURE 18 A & B.

Endogenous Measurements of AA and DHAA in

Diabetic and Nondiabetic Rat Adrenal Glands Figure 18 A
presents the measurement of endogenous AA in diabetic and
nondiabetic rat adrenal glands. Figure 18 B presents the
measurements of endogenous DHAA in diabetic and nondiabetic rat
adrenal glands calculated from measured total AA (AA + DHAA) and
endogenous AA.
* p < 0.05 for diabetic compared to nondiabetic measurements
ND = not detectable

72

cd

i—

20000

O)
■p
'o
<
o
i—

100001

o
o

cr)
<
"o

CONTROL

DIABETIC

nmol Dehvdroascorbic

(A )

600
500-

.. *.... ... — ....... ».—.11

CONTROL
(B)

DIABETIC

FIGURE 19.

R eco ve ry o f E x o g e n o u s A A and D H AA

One mM AA and 1

mM DHAA were added to diabetic and nondiabetic tissues used in the analysis
of endogenous levels of AA and DHAA. Recoveries in brain, kidney and liver
tissues were evaluated and grouped into diabetic and nondiabetic
measurements.
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APPENDIX B
KEY TO A B B R E V IA T IO N S USED IN TEXT
C om pounds
AA

Ascorbic acid

APR

Ascorbate free radical

B a (0 H )28H20

Barium hydroxide

DHAA

Dehydroascorbic acid

DKG

2,3-diketogulonic acid

EDTA

Ethylenediam inetetraacetic
acid

MFO

Mixed function oxidase

n

Nitrogen

2

NADH

Nicotinamide adenine
dinucleotinde, reduced form

PAM

Peptidylglycine a-am idating
m onooxygenase

TCA

Trichloroacetic acid

Z n S 0 47H 20

Zinc Sulfate

Units of Measurement
g

Gram

L

liter

M

Molar (moles / liter)

m

milli

75

76
min

minute

mol

m oles

n

nano (10'9)

P

pico (10"12)

P

micro (10‘ 6)

V

Volts

M iscellaneous
E°'

Formal potential

E 1/2

Half-wave potential

EC

Electrochemical

9

Acceleration of gravity

HPLC

High-perform ance liquid
chrom atography

pH

-log hydrogen ion
concentration
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